Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
Crexendo Chief Strategy Officer Anand Buch sold 88,000 shares across two transactions on March 11 and March 13, 2026, according to a Form 4 filing, generating $579,200. The company reported fourth-quarter 2025 earnings that beat EPS expectations while revenue fell marginally short of estimates, and announced an acquisition of ESI that prompted Need…
Alpha Metallurgical Resources director Kenneth S. Courtis bought 10,000 shares on March 11, 2026, spending $1.8 million at prices between $185.28 and $187.87. The insider purchases come as the company reported a disappointing Q4 2025 with EPS and revenue misses, and as analysts kept Hold ratings while trimming price targets.
Kurt L. Kalbfleisch, CEO and CFO of Sphere 3D Corp (NASDAQ: ANY), sold 9,800 shares on March 13, 2026 for $1.59 per share, netting $15,582. The sale came one day after he exercised restricted stock units to acquire 18,358 shares. The company has recently regained Nasdaq minimum bid-price compliance, approved corporate governance measures at a speci…
Tiah Norton Reppas, Chief Accounting Officer of Sphere 3D Corp (NASDAQ: ANY), sold 6,250 shares on March 12, 2026 for $1.61 per share, totaling $10,062. The transaction followed an exercise of restricted stock units the day before and comes as the company reports regained Nasdaq minimum bid price compliance, a 1-for-10 reverse stock split, and shar…
Apogee Therapeutics CEO Michael Thomas Henderson sold 19,990 shares of company stock on March 11, 2026, under a Rule 10b5-1 plan adopted in August 2025. The trades, executed at prices between $74.29 and $75.86, reduced Henderson's direct holdings to 1,152,987 shares. The sale occurs amid strong share gains over the past year and a mix of analyst re…
Texas Roadhouse Chief Technology Officer Hernan E. Mujica sold 5,000 shares on March 13, 2026, for roughly $850,000. The transaction comes after the company reported fourth-quarter 2025 earnings that missed expectations, prompting mixed analyst revisions driven by beef inflation, weather disruptions and labor inefficiencies.
Fox Corporation Executive Chair and CEO Lachlan Murdoch executed a series of stock sales of Class A Common Stock between March 11 and March 13, 2026, totaling approximately $65.4 million. The transactions, disclosed on a Form 4, include multiple block sales, an exchange with the LKM Family Trust, and option exercises. The activity occurred while Fo…
John Nallen, President and Chief Operating Officer of Fox Corporation, disposed of $26.5 million in Class A Common Stock across multiple trades on March 11 and 12, 2026, while simultaneously exercising options to acquire 459,115 shares. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted December 2, 2025. Fox reported a…
Sarepta Therapeutics director Stephen Mayo sold 7,239 shares of common stock on March 12, 2026, at $17.02 per share for $123,207 to satisfy tax obligations arising from vested restricted stock units. The transaction leaves Mayo with 1,765 shares directly held. Sarepta shares were trading near $16.40, a decline of 84% from their 52-week high of $103…
Confluent, Inc. Chief Financial Officer Sivaram Rohan sold 29,996 Class A shares on March 12, 2026, generating about $919,977. The disposition, carried out under a 10b5-1 trading plan established in December 2025, leaves Rohan with 531,971 shares. The move comes while Confluent stock trades close to its 52-week peak amid strong six-month performanc…
Andrew M. Cohn, a director at Global Water Resources, Inc. (NASDAQ:GWRS), made two recent purchases of company common stock in March 2026, including an $131,796 acquisition. The transactions leave Cohn with more than 2.56 million shares directly and 42,150 indirectly. The moves coincide with the stock trading near its 52-week low and follow recent …
Maria Georgia Magno, Chief Legal Officer at Baker Hughes Co (BKR), sold 5,063 Class A shares on March 11, 2026, under a previously established Rule 10b5-1 plan. The transaction totaled $298,919. After the sale Magno holds 15,555.296 shares. The company has recently issued $9.5 billion of debt to finance the Chart Industries acquisition and secured …
Framework Ventures IV L.P. bought 29,494 shares of Better Home & Finance Holding Co. (NASDAQ: BETR) on March 13, 2026, at $34.12 per share for a total of $1,006,335, raising its direct holdings to 834,312 shares. The transaction sits alongside the company’s reported strong fourth-quarter 2025 results and management commentary pointing to progress o…
Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals (LGND), sold 3,057 shares on March 11, 2026, for $225.00 per share, realizing $687,825. He also exercised options for 2,405 shares at $92.65, a transaction valued at $222,823. The moves were carried out under a trading plan adopted November 19, 2025; after the sale Espinoza directl…
Jarvis Scot B., a director at Kratos Defense & Security Solutions (KTOS), sold 5,000 shares on March 12, 2026, for $88.6 per share, generating $443,000. The transaction, carried out under a pre-existing 10b5-1 plan adopted September 15, 2025, leaves Jarvis with 85,417 shares. The sale occurs alongside several corporate developments including a $7 m…
Dawn Christine Maroney, president of Alignment Healthcare, sold 29,113 shares on March 12, 2026, in transactions totaling $507,925 to satisfy tax-withholding obligations tied to vested restricted stock units. The sales were non-discretionary; Maroney retains a substantial direct stake in the company. The stock has recently traded lower, while third…
Alignment Healthcare Chief Information Officer Robert L. Scavo sold 4,044 shares on March 12, 2026, in two transactions totaling $70,554. The sales were executed to satisfy tax withholding obligations tied to restricted stock units and do not reflect discretionary trading. The moves occur as the shares trade near $17 and amid a separate secondary o…
Alignment Healthcare CEO John E. Kao disposed of 48,900 shares on March 12, 2026, in two SEC-reported transactions totaling $853,125. The sales were reported as covering tax-withholding obligations tied to restricted stock unit vesting and were not described as discretionary trades. The company recently delivered robust fourth-quarter metrics, and …
Jeffrey Jacob Raider, a director at Warby Parker Inc. (WRBY), sold 25,000 shares of Class A common stock on March 11, 2026, for roughly $635,750 in multiple trades at prices between $25.17 and $25.69. The transaction leaves Raider with substantial direct and indirect holdings while Warby Parker navigates an earnings shortfall, modest revenue varian…
Hugo E. Gonzalez, President of Powersports & Housing and Chief Operating Officer at Patrick Industries Inc. (NASDAQ: PATK), disposed of 13,514 shares on March 12, 2026, for $1.53 million. The sale occurred at a weighted average price of $113.096 per share in multiple transactions between $112.10 and $114.025. After the trades, Gonzalez directly hol…
Fabian Gomez, president of Westwood Holdings Group Inc (WHG), sold 6,223 shares on February 23, 2026, at $16.22 per share for a total of $100937 and simultaneously acquired 32,287 shares the same day. After these moves he directly holds 122,573 shares. Westwood reported Q4 2025 revenues of $27.1 million versus $25.6 million a year earlier and noted…
Andrew D. Vogel, executive vice president and president of meals at B&G Foods, sold 20,000 shares on March 13, 2026, receiving $103,762. The insider transaction occurs amid B&G Foods' mixed fourth-quarter 2025 results, an announced divestiture of the Green Giant frozen business, and plans to acquire College Inn/KB. Multiple analysts adjusted price …
Thomas Andrew Rowland, senior vice president and head of established brands at ANI Pharmaceuticals, sold 4,772 shares on March 11, 2026, for $74.91 per share, totaling $357,470. The company recently reported a better-than-expected fourth quarter of 2025, yet the stock was trading below the sale price and experienced a premarket decline. Independent…
Christopher Mutz, head of Rare Disease at ANI Pharmaceuticals, sold 3,162 shares of company stock on March 13, 2026, in a transaction valued at $226,525. The sale was carried out under a Rule 10b5-1 plan adopted June 16, 2025. ANI reported fourth-quarter 2025 earnings and revenue that exceeded forecasts, but the stock traded lower in premarket acti…
QuantumScape Chief Financial Officer Kevin Hettrich executed a sale of 9,800 Class A shares on March 11, 2026, under a Rule 10b5-1 plan adopted in June 2025, generating proceeds of $68,126. The company is navigating volatile equity performance, analyst reassessments and a new board appointment while unrelated industry funding news highlights activi…
